Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huaming Tan

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
International Journal of Radiation Oncology, Biology, Physics|August 16, 2005
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatmentMin Yao, Russell B Smith, Michael M Graham, et al.
American Journal of Clinical Dermatology|July 3, 2019
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsValerie D Callender, Andrew F Alexis, Linda F Stein Gold, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
American Journal of Clinical Oncology|December 7, 2006
Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future researchMin Yao, Thanh Nguyen, John M Buatti, et al.
Acta Dermato-Venereologica|March 22, 2019
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation AnalysisEric L Simpson, Gil Yosipovitch, Andrew G Bushmakin, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2005
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experienceMin Yao, Kenneth J Dornfeld, John M Buatti, et al.
Journal of the American Academy of Dermatology|February 23, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension studyKim A Papp, James G Krueger, Steven R Feldman, et al.
Lancet (London, England)|June 9, 2015
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trialHervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
International Journal of Radiation Oncology, Biology, Physics|August 16, 2005
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatmentMin Yao, Russell B Smith, Michael M Graham, et al.
American Journal of Clinical Dermatology|July 3, 2019
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic GroupsValerie D Callender, Andrew F Alexis, Linda F Stein Gold, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
American Journal of Clinical Oncology|December 7, 2006
Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future researchMin Yao, Thanh Nguyen, John M Buatti, et al.
Acta Dermato-Venereologica|March 22, 2019
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation AnalysisEric L Simpson, Gil Yosipovitch, Andrew G Bushmakin, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2005
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experienceMin Yao, Kenneth J Dornfeld, John M Buatti, et al.
Journal of the American Academy of Dermatology|February 23, 2016
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension studyKim A Papp, James G Krueger, Steven R Feldman, et al.
Lancet (London, England)|June 9, 2015
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trialHervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
Pageof 4